| Company Name: | CuraGen Corporation | | Ticker Symbol: | CRGN | | | WWW Address: | www.curagen.com |
| CEO: | Dr. Timothy M. Shannon, M.D. | | No. of Employees: | 16 |
| Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, which is engaged in the development of novel therapeutics for the treatment of cancer.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.44 |  0.0 | - | - | | 1.47 | 1.40 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 82.4 | 57.2 | 1.45 | 0.44 | 0.00 | 0.0 | 0.0 | 1.48 - 0.41 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.44 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 82.4 | mil |
| Latest Shares Outstanding | 57.2 | mil |
| Earnings pS (EPS) | 0.44 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 73,375 | $ |
| Effective Tax Rate | 1.3 | % |
| Float | 55.9 | mil |
| Float as % of Shares Outstanding | 97.7 | % |
| Foreign Sales | 1 | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -18.1 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -18.8 | % |
| Current Ratio | 26.8 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.24 | |
| LT Debt/Total Capital | 19.0 | % |
| Working Capital pS | 1.29 | $ |
| Cash pS | 0.99 | $ |
| Book-Value pS | 1.05 | $ |
| Tangible Book-Value pS | 1.05 | $ |
| Cash Flow pS | -0.24 | $ |
| Free Cash Flow pS | -0.25 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.37 | |
| Price/Tangible Book Ratio | 1.37 | |
| Price/Cash Flow | -6.0 | |
| Price/Free Cash Flow | -5.8 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 11.6 | 114 | 7,580 | 46,460 |
| 4 Weeks | 1.47 | 1.25 | 1.39 | 3.6 | 103 | 5,613 | 106,648 |
| 13 Weeks | 1.47 | 1.25 | 1.42 | 1.4 | 89 | 3,946 | 252,552 |
| 26 Weeks | 1.48 | 0.85 | 0.90 | 60.0 | 131 | 5,734 | 722,534 |
| 52 Weeks | 1.48 | 0.41 | 0.72 | 100.0 | 214 | 3,545 | 889,727 |
| YTD | 1.48 | 0.47 | - | 213.0 | 276 | 4,157 | 789,893 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.42 | 1.38 | 1.39 | 1.21 | 1.05 | 1.45 | 1.09 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -77.41 | NA | -93.12 |
| R&D | -29.71 | NA | -43.26 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -100.0 | -100.0 | 1234.1 |
| Earnings % | -100.0 | -100.0 | -2.4 |
| EPS % | -100.0 | -100.0 | -2.2 |
| EPS $ | -0.65 | -0.73 | -0.01 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 94.92 |
| Current Ratio | 21.4 |
| Quick Ratio (Acid Test) | 21.4 |
| Liquidity Ratio (Cash) | 21.31 |
| Receivables Turnover | 3.3 |
| Average Collection Period | 109 |
| Working Capital/Equity | 128.4 |
| Working Capital pS | 1.47 |
| Cash-Flow pS | 0.44 |
| Free Cash-Flow pS | -0.35 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.67 |
| Financial Leverage Ratio (Assets/Equity) | 1.4 |
| Debt Ratio | 26.1 |
| Total Debt/Equity (Gearing Ratio) | 0.29 |
| LT Debt/Equity | 0.29 |
| LT Debt/Capital Invested | 22.5 |
| LT Debt/Total Liabilities | 82.2 |
| Interest Cover | 15.9 |
| Interest/Capital Invested | 2.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.38 |
| Tobin's Q Ratio | 0.93 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -0.96 |
| Enterprise Value (EV)/Free Cash Flow | 0.21 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 1.37 |
| Price/Book Ratio - LTM | 1.37 |
| Price/Cash Flow Ratio | -6.0 |
| Price/Free Cash Flow Ratio - LTM | -5.8 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 2.0 |
| P/E Ratio (52 weeks ago) - LTM | 2.4 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.33 |
| Current Liabilities pS | 0.07 |
| Tangible Book Value pS - LTM | 1.05 |
| Book Value pS - LTM | 1.05 |
| Capital Invested pS | 1.48 |
| Cash pS - LTM | 0.99 |
| Cash Flow pS - LTM | -0.24 |
| Free Cash Flow pS - LTM | -0.25 |
| Earnings pS (EPS) | 0.44 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -1,698.21 |
| Free Cash Flow Margin 5YEAR AVG | -10,699.55 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.02 |
| Return on Equity (ROE) | 37.9 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.01 |
| Return on Capital Invested (ROCI) | 29.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -19.4 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | 28.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -16.1 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 1.3 |
| Effective Tax Rate - 5YEAR AVRG. | 0.8 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 87 |
| Revenue per Employee | 73,375 |
| Net Income per Employee | 1,548,813 |
| Average Collection Period | 87 |
| Receivables Turnover | 3.3 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 20.36 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.01 |
| Fixed Assets Turnover | 3.03 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.06 |
| Revenue per $ Plant | 11.51 |
| Revenue per $ Common Equity | 0.02 |
| Revenue per $ Capital Invested | 0.01 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 438.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 109.0 |
| Research & Devlopment (R&D) as % of Revenue | 1284.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 1284.2 |
|
|  
|
| |
 |  |
